Equities Analysts Issue Forecasts for RNTX FY2030 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Analysts at HC Wainwright boosted their FY2030 EPS estimates for shares of Rein Therapeutics in a research report issued on Monday, June 1st. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.55 per share for the year, up from their prior forecast of $0.43. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.63) per share.

Rein Therapeutics (NASDAQ:RNTX) last announced its earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30.

Separately, Wall Street Zen upgraded shares of Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Rein Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.00.

Rein Therapeutics Price Performance

NASDAQ:RNTX opened at $1.07 on Tuesday. The firm’s fifty day moving average price is $1.32 and its 200 day moving average price is $1.30. Rein Therapeutics has a 1-year low of $0.95 and a 1-year high of $2.18. The firm has a market cap of $91.53 million, a price-to-earnings ratio of -0.56 and a beta of 1.35.

Institutional Investors Weigh In On Rein Therapeutics

Institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP purchased a new stake in shares of Rein Therapeutics during the 3rd quarter worth $35,000. HRT Financial LP purchased a new stake in shares of Rein Therapeutics during the 4th quarter worth $38,000. Chicago Partners Investment Group LLC boosted its position in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after buying an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Rein Therapeutics in the 2nd quarter worth about $68,000. Finally, Jane Street Group LLC purchased a new stake in shares of Rein Therapeutics in the 4th quarter worth about $72,000. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.